

## 2025

### 英文論文

1. 2025 Matsubara T, Hagiwara S, Nishida N, Omaru N, Yoshida A, Yamamoto T, Komeda Y, Takenaka M, **Kudo M**: Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B. **Sci Rep** 15:869, 2025. (IF=3.90)
2. 2025 Rubin D, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KHG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A, **Kudo M**, QUASAR Study Group: Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. **Lancet** 405:33-49, 2025. (IF=88.50)
3. 2025 Furuse J, Izumi N, Motomura K, Inaba Y, Katamura Y, Kondo Y, Yabushita K, Matsuoka T, Motoyoshi K, **Kudo M**: Long-term survival of patients with unresectable hepatocellular carcinoma treated with lenvatinib in real-world clinical practice. **Cancers** 17:479, 2025. <https://doi.org/10.3390/cancers17030479> (IF=4.40)
4. 2025 Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Hirooka M, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Ito K, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, **Kudo M**, Kumada T: Evaluation of treatment outcomes using dNLR and GNRI in combination therapy with atezolizumab and bevacizumab for hepatocellular carcinoma. **Cancer Med** 14:e70618, 2025. doi: 10.1002/cam4.70618. (IF=3.10)
5. 2025 Sangro B, **Kudo M**, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y,

2025

英文論文

- Heo J, Mai A, Escobar J, Chuken YAL, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lension R, on behalf of the EMERALD-1 Investigators: Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. **Lancet** 405:216-232, 2025. (IF=88.50)
6. 2025 **Kudo M**<sup>†</sup>, Ren Z<sup>†</sup>, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madccoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS<sup>†</sup>, Llovet JM<sup>†</sup>, and the LEAP-012 investigators: Transarterial chemoembolisation combined with Lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. **Lancet** 405:203-215, 2025. (†Shard 1<sup>st</sup> authors) (IF=88.50)
7. 2025 Morimoto-Ishikawa D, Hyodo T, Komeda Y, Fukushima H, Itoh M, Ueda Y, **Kudo M**, Saito S, Ishii K: Quantitative evaluation of noncontrast magnetic resonance enterography for active inflammation in crohn disease using native T1 and T2 mapping. **J Comput Assist Tomogr** 49:1-8, 2025. (IF=1.30)
8. 2025 Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, Dao TV, Kang YK, Thungappa SC, **Kudo M**, Sangro B, Kelley RK, Furuse J, Park JW, Sunpaweravong P, Fasolo A, Yau T, Kawaoka T, Azevedo S, Reig M, Assenat E, Yarchoan M, He AR, Makowsky M, Gupta C, Negro A, Chan SL: Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. **J Hepatol** 82:258-267, 2025. (IF=33.00)

2025

英文論文

9. 2025 Kawano K, Takenaka M, Kawano R, Kagoshige D, Mine K, Nishi K, **Kudo M**: A novel clip with mantis-like claws combined with the over-the-scope clip for fistula closure. **Endoscopy** 57:E130-E132, 2025. (IF=12.80)
10. 2025 Kodama Y, Ueshima K, Moriguchi M, Inaba Y, Yamashita T, Iwamoto H, Ueno M, Ogasawara S, Kuzuya T, Kodama T, Sato Y, Tada T, Tsuchiya K, Nishiofuku H, Yamakado K, Sone M, Ikeda M, Takehara T, Hamano T, **Kudo M**\*: Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. **BMC Cancer** 25:434, 2025. doi: 10.1186/s12885-025-13648-5. (IF=3.40)
11. 2025 Minaga K, Watanabe T, Hara A, Yoshikawa T, Kamata K, **Kudo M**: Gut microbiota involved in the immunopathogenesis of autoimmune pancreatitis. **Gut Liver** 19:171-176, 2025. (IF=3.20)
12. 2025 Hara A, Watanabe T, Minaga K, Kamata K, Strober W, **Kudo M**: Sequential activation of conventional and plasmacytoid dendritic cells in autoimmune pancreatitis and systemic lupus erythematosus: similarities and dissimilarities. **Front Immunol** 16:1554492, 2025. (IF=5.90)
13. 2025 Yamakawa M, Shiina T, Nishida N, **Kudo M**: Study on the optimal ROI cropping condition for each liver tumor type to improve the sensitivity of convolutional neural network for liver tumor ultrasound image classification. **Jpn J Appl Phys** 64:03SP24, 2025. DOI 10.35848/1347-4065/adb6b4 (IF=1.80)
14. 2025 Li XQ, Cheng GW, Akiyama I, Huang XJ, Liang J, Xue LY, Cheng Y, **Kudo M**, Ding H: Attenuation imaging: diagnostic

2025

英文論文

- differences in hepatic steatosis for chronic hepatitis B vs. metabolic dysfunction-associated steatotic liver disease patients. **World J Gastroenterol** 31:102795, 2025. (IF=5.40)
15. 2025 **Kudo M**\*: Lenvatinib plus pembrolizumab combined with transarterial chemoembolization in intermediate-stage hepatocellular carcinoma. **Liver Cancer** 14:1-7, 2025. (IF=9.10)
16. 2025 Aoki T, Nishida N, Minami Y, **Kudo M**\*: The impact of normal hepatobiliary cell zonation programs on the phenotypes and functions of primary liver tumors. **Liver Cancer** 14:92-103, 2025. (IF=9.10)
17. 2025 Stefanini B, Fulgenzi CAM, Scheiner B, Korolewicz J, Cheon J, Nishida N, Ang C, Marron TU, Wu YL, Saeed A, Wietharn B, Rimassa L, Pirozzi A, Cammarota A, Pressiani T, Pinter M, Balcar L, Huang YH, Mehan A, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Samson A, Galle PR, **Kudo M**, Manfredi GF, Celsa C, Awosika N, Cortellini A, Singal AG, Sharma R, Chon HJ, Tovoli F, Piscaglia F, Pinato DJ, D'Alessio A: ALBI grade enables risk stratification for bleeding events and refines prognostic prediction in advanced HCC following atezolizumab and bevacizumab. **J Hepatocell Carcinoma** 12:671-383, 2025. (IF=3.40)
18. 2025 Takenaka M, **Kudo M**: What has changed and remained the same in the past 55 years regarding the prediction and prevention of post-ERCP pancreatitis? **Digest Endosc** 37:373-375, 2025. (IF=4.70)
19. 2025 Matono T, Tada T, Kumada T, Hiraoka A, Hiroka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Ito K, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H,

2025

英文論文

- Naganuma A, Aoki T, Kuroda H, Yata Y, Nakamura Y, Yoshida O, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, **Kudo M**, on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group: Survival outcomes associated with radiological progressive disease subtypes in patients with atezolizumab and bevacizumab-treated HCC. **J Gastroen Hepatol** 40:949-959, 2025. (IF=3.40)
20. 2025 **Kudo M**\*: Treatment decision making in unresectable hepatocellular carcinoma: Importance to understand the different response patterns between IO plus anti-VEGF and IO plus IO regimens. **Liver Cancer** 14:119-126, 2025. (IF=9.10)
21. 2025 Okushin K, Tateishi R, Hirakawa S, Tachimori H, Uchino K, Nakagomi R, Yamada T, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Yoshiji H, Izumi N, **Kudo M**, Koike K: Comparable outcomes among etiologies in early-stage hepatocellular carcinoma: An analysis of a nationwide registry in Japan. **Hepatol Res** 55:556-566, 2025. (IF=3.40)
22. 2025 Naganuma A, Kakizaki S, Hatanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Matsui K, Yata Y, Tanaka H, Ohama H, Kuroda H, Matono T, Aoki T, Ochi H, Imai M, Nakamura S, Kanayama Y, Tanaka K, Tada F, Yoshida O, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Enomoto H, Kaibori M, Hiasa Y, **Kudo M**, Kumada T: Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study. **Hepatol Res** 55:741-751, 2025. (IF=3.40)
23. 2025 **Kudo M**\*: Immune checkpointInhibitor plus anti-VEGF/TKI

2025

英文論文

combined with transarterial chemoembolization in locally advanced nonmetastatic hepatocellular carcinoma: Real-world treatment strategy based on phase 3 clinical trial results. **Liver Cancer** 14:241-247, 2025. (IF=9.10)

24. 2025 Aoki T, **Kudo M**\*, Nishida N, Ueshima K, Tsuchiya K, Tada T, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Kuroda H, Nakamura N, Hiraoka A, Tomonari T, Tani J, Naganuma A, Kakizaki S, Ogawa C, Hatanaka T, Ishikawa T, Kawata K, Takebe A, Matsumoto I, Hidaka M, Kurosaki M, Kumada T, Izumi N: Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study. **J Gastroenterol** 60:738-753, 2025. (IF=5.50)
25. 2025 Scheiner B, Kang B, Balcar L, Radu IP, Reiter FP, Adžić G, Guo J, Gao X, Yuan X, Cheng L, Gorgulho J, Schultheiss M, Peeters F, Hucke F, Khaled NB, Piseddu I, Philipp A, Sinner F, D'Alessio A, Pomej K, Saborowski A, Bathon M, Schwacha-Eipper B, Zarka V, Lampichler K, Nishida N, Lee PC, Krall A, Saeed A, Himmelsbach V, Tesini G, Huang YH, Vivaldi C, Masi G, Vogel A, Schulze K, Trauner M, Djanani A, Stauber R, **Kudo M**, Parikh ND, Dufour JF, Prejac J, Geier A, Bengsch B, von Felden J, Venerito M, Weinmann A, Radosavljevic MP, Finkelmeier F, Dekerverl J, Ji F, Wang HW, Rimassa L, Pinato DJ, Bouattour M, Chon HJ, Pinter M: Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy. **Hepatology** 81:1714-1727, 2025. (IF=15.80)
26. 2025 Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ohama H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tada F,

2025

英文論文

- Nakamura S, Nakamura Y, Nouse K, Morishita A, Itokawa N, Okubo T, Arai Y, Tsutsui A, Nagano T, Tanaka K, Tanaka H, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Kaibori M, Hiasa Y, **Kudo M**, Kumada T, on behalf of the RELPEC Group and HCC 48 Group: Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice. **Hepatol Res** 55:444-453, 2025. (IF=3.40)
27. 2025 Finn RS, Gu K, Chen X, Merle P, Lee KH, Bouattour M, Cao P, Wang W, Cheng AL, Zhou L, Lim HY, **Kudo M**, Pan Y, Chang TT, Edeline J, Li W, Yang P, Li C, Li J, Siegel AB, Qin S: Second-line pembrolizumab for advanced HCC: meta-analysis of the phase 3 KEYNOTE-240 and KEYNOTE-394 studies. **JHEP Reports** 7:1-9, 2025. (IF=7.50)
28. 2025 Finn RS, **Kudo M**, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Cheng AL, Galle PR, Kaneko S, Kumada H, Kamble S, Norquist JM, Mody K, Wang A, Dubrovsky L, Llovet JM: Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma, **ESMO Open** 10, 2025.  
<https://doi.org/10.1016/j.esmoop.2025.105065> (IF=8.30)
29. 2025 Takenaka M, Fukunaga T, Nakai A, Omoto S, Kwon CI, **Kudo M**: Impact of rotation direction on treating common bile duct stones with an asymmetrical 8-wire helical basket. **Endoscopy** 57:E443-E444, 2025. (IF=12.80)
30. 2025 Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Pena AM, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Exposito MJJ, **Kudo M**: Nivolumab plus ipilimumab versus lenvatinib or sorafenib as

2025

英文論文

- first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): a randomised, open-label, phase 3 trial. **Lancet** 405:1851-1864, 2025. (IF=88.50)
31. 2025 Yamao K, Takenaka M, Yoshida A, Yamazaki T, Omoto S, Minaga K, Kamata K, Takada Y, Uetsuki K, Iida T, Mizutani Y, Ishikawa T, Kawashima H, **Kudo M**: Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and identifies high-risk patients. **Pancreatology** 25:307-314, 2025. (IF=2.70)
32. 2025 Kurimoto M, Honjo H, Yoshida S, Okai N, Otsuka Y, Masuta Y, Masaki S, Kamata K, Minaga K, Maenishi O, **Kudo M**, Watanabe T: Enlargement of gastric hyperplastic polyps arising from helicobacter heilmannii sensu stricto-infected mucosa after the successful eradication of helicobacter pylori and the long-term use of a proton pump inhibitor. **Intern Med** 64:1677-1683, 2025. (IF=1.10)
33. 2025 Hatanaka T, Yata Y, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Kakizaki S, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Matsui K, Naganuma A, Tanaka H, Ohama H, Kuroda H, Matono T, Aoki T, Ochi H, Imai M, Nakamura S, Kanayama Y, Tanaka K, Tada F, Yoshida O, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Enomoto H, Kaibori M, Hiasa Y, **Kudo M**, Kumada T, on behalf of the Real-life Practice Experts for HCC Study Group and HCC 48 Group: Clinical impact of serum CRP levels on advanced HCC treated with durvalumab and tremelimumab: A multicentre study. **Liver Int** 45:e70192. 2025. (IF=5.2)
34. 2025 Matono T, Tada T, Kumada T, Hiraoka A, Hiroka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama

2025

英文論文

- Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Tamai H, Matsuura T, Komatsu S, Ueda Y, Nakamura Y, Yoshida O, Matsui K, Nakamura S, Enomoto H, Kaibori M, Fukumoto T, Hiasa Y, **Kudo M**, on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group: Vascular invasion within the resectability criteria is a prognostic factor in patients treated with atezolizumab and bevacizumab. **Liver Int** 45:e70217, 2025. (IF=5.2)
35. 2025 Minaga K, Honjo H, Watanabe T, **Kudo M**: Shining stars in the sky on the gastric mucosa. **J Gen Fam Med** 26:368-369, 2025. (IF=2.3)
36. 2025 Omaru N, Watanabe T, Hara A, Kurimoto M, Masuta Y, Otsuka Y, Masaki S, Minaga K, Kamata K, Honjo H, Arai Y, Yamashita K, **Kudo M**: Dysregulated pro-inflammatory and anti-inflammatory cytokine responses to microbe-associated molecular patterns in patients with X-linked chronic granulomatous disease. **In Vivo** 39:1902-1911, 2025. (IF=1.8)
37. 2025 **Kudo M**, Oanh BT, Chen CJ, Ngat DT, George J, Kim DY, Pimsawadi L, Tangkijvanich P, Pwu RF, Mohamed R, Bunnag S, Lu SN, Kudtiyakarn S, Kanto T, Piratvisuth T, Wu CC, Sarno R, on behalf of the APAC Liver Disease Alliance: Roadmap for HCC surveillance and management in the Asia Pacific. **Cancers** 17:1928, 2025. (IF=4.4)
38. 2025 Kurimoto M, Watanabe T, **Kudo M**: Novel immunotherapy for multiple myeloma involving activation of plasmacytoid dendritic cells. **Mol Ther Oncol** 33:201004, 2025. (IF=5.3)
39. 2025 Takenaka M, **Kudo M**: Assessment of endoscopic ultrasound-

2025

英文論文

guided hepaticogastrostomy as a feasible option for preoperative biliary drainage before pancreaticoduodenectomy. **Clin Endosc** 58:549-551, 2025. (IF=2.3)

40. 2025 Panaccione R, Feagan BG, Afzali A, Rubin DT, Reinisch W, Panés J, Danese S, Hisamatsu T, Terry NA, Salese L, Van Rampelbergh R, Sahoo A, Vetter ML, Yee J, Han C, Frustaci ME, Wan KYY, Yang Z, Johanns J, Andrews JM, D'Haens GR, Sands BE, Abdelli MN, Farsakh NA, Omary AA, Ala S, Alexeeva O, Allamehzadeh R, Annese V, Arlukowicz T, Arya N, Augustyn M, Ausaf N, Avni-Biron I, Bacci M, Balaz J, Barker M, Bedran K, Begun J, Beloborodova E, Bernstein C, Bhakhar P, Bhanvadia A, Bilianskyi L, Blumenstein I, Boratto S, Borsuk A, Bortlik M, Bossa F, Boubaker J, Bullock J, Bullock M, Bunkova E, Cadiot G, Cao Q, López DC, Cerqueira R, Cesarz M, Chamouard P, Chen B, Chen H, Chen X, Chen Y, Chiplunker A, Chiu CT, Chun J, da Silva Junior R, Dai WJ, Danilkiewicz W, Datsenko O, De Cruz PP, Deriban G, Ding S, Ding Y, Duszynska M, DuVall G, Piudo AE, Felicio O, Ferreira D, Filip R, Fominykh Y, Fon J, Francesconi C, Friedenber K, Frysna B, Fujii T, Furmanowska-Ladorska E, Gao X, Gasbarrini A, Gawdis-Wojnarska B, Gearry R, Gionchetti P, Gniady-Jastrzebska J, Goldin E, Golovchenko O, Gornjakovic S, Gridnyev O, Casallas LG, Harlan W, Hébuterne X, Heeren S, Ramírez VH, Hilmi IN, Horiki N, Hoshi N, Hotayt B, Hou X, Hu N, Huang V, Iakovlev A, Ikeda T, Ishigami K, Ishiguro Y, Ito H, Izbéki F, Jain A, Jairath V, Jamrozik-Kruk Z, Janik K, Jochum C, Jovicic I, Kaiser Junior RL, Kagaya T, Kanda T, Kang B, Kang SB, Khan G, Kierkus J, Kim SE, Kim TO, Kim YH, Klaus J, Kleczkowski D, Kojima Y, Koo JS, Korga P, Kowalski M, Kralj D, Ksiao M, **Kudo M**, Kunisaki R, Kusunoki R, Kwinto M, Kyrychenko O, Laclav M, Lee KM, Leong R, Leszczyszyn J, Lim A, Liu M, Liu W, Löwenberg M, Lukas M, Macrae F, Makishi T, Marina P, Machavariani A, Mateo MM, Matsumoto T, Matsuoka K, Matsushima K, Mehta R, Mihaly E, Motoya S, Mroziak B, Muls V, Nancey S, Nishida A, Novák J, Oliinyk O, Olszanecka-

2025

英文論文

Glinianowicz M, Ono Y, Osada T, Osipenko M, Osman M, Over H, Alahdab YO, Parente JM, Park DII, Park SH, Patel B, Patel K, Peerani F, Petroniene R, Petryka R, Peyrin-Biroulet L, Pilav A, Pokrotnieks J, Pratha V, Pugliese D, Pukitis A, Raine T, Rainis T, Randall C, Rashid M, Rayyan Y, Reindl W, Ritter T, Roblin X, Rocca R, Rojek-Margas B, Rolim A, Romanczyk T, Rowbotham D, Sag Si, Sakakibara Y, Salamon A, Sanchez M, Saranovic-Ceco L, Saruta M, Sasaki L, Scherl E, Schiefke I, Schnoy E, Schreiber S, Schultz M, Seidler U, Shah N, Shah S, Shariff MK, Shchukina O, Shi H, Shimizu M, Shukla R, Siegel J, Simanenkov V, Neto JS, Slankamenac D, Smid V, Smolinski P, Soofi N, Sparrow M, Sreckovic S, Suzuki T, Takayama T, Takeuchi K, Takeuchi M, Tamaki H, Tanaka H, Tanash O, Tarabar D, De Sousa MHT, Tian F, Tiongco F, Tkachev A, Tomasic V, Trofimov V, Ueo T, Uzzan M, Valuyskikh E, van Bodegraven A, Van Domselaar M, Varga M, Vasconcellos E, Fernandes JV, Volfova M, Voska M, Vuitton L, Watanabe K, Wei SC, Weintraub A, Wojcik K, Wolf D, Wojtowicz J, Xiao W, Yanagisawa H, Zajac P, Zaltman C, Zhang J, Zhang Y, Zhong J, Zhong L, Zhu L, Zhu Y, Zittan E, Zmudzinski M, Zou X: Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials. **Lancet** 406:358-375, 2025. (IF=88.5)

41. 2025 Manfredi GF, Fulgenzi CAM, Celsa C, Stefanini B, D'Alessio A, Pinter M, Scheiner B, Awosika N, Brunetti L, Lombardi P, Latchford C, Lee PC, Huang YH, Lin CY, Dalbeni A, Vogel A, Galle PR, **Kudo M**, Rimassa L, Chon HJ, Pinato DJ: Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence. **JHEP Reports** 7:101431, 2025. (IF=7.5)

42. 2025 **Kudo M\***: Depth of response predicts survival in unresectable

2025

英文論文

- hepatocellular carcinoma treated with immunotherapy: Not all stable disease is equal. **Liver Cancer** 14:357-364, 2025. (IF=9.1)
43. 2025 Kawaguchi Y, Hasegawa K, Kashiwabara K, Okamura Y, Kurosaki M, **Kudo M**, Shimada M, Yamanaka N, Inomata M, Yamashita T, Tateishi R, Shina S, Fujishiro M, Matsuyama Y, Omata M, Kokudo N: Surgery versus ablation for hepatocellular carcinoma: A randomized controlled trial (SURF-RCT Trial) and a nonrandomized prospective observational trial (SURF-Cohort Trial). **J Clin Oncol** 43:2628-2638, 2025. (IF=41.9)
44. 2025 Minami Y, Sugimoto K, Kuroda H, Kamiyama N, Ogawa C, **Kudo M**: Differentiating between hepatocellular carcinoma and its mimickers using contrast-enhanced ultrasound with perflubutane microbubbles. **Expert Rev Med Devic** 22:817-826, 2025. (IF=2.7)
45. 2025 Tanaka H, Takenaka M, Masuta Y, Minaga K, Kawano K, **Kudo M**: A novel endoscopic lithotripsy technique for a huge common bile duct stone: endoscopic snare lithotripsy. **Endoscopy** 57: E949-E951, 2025. (IF=12.8)
46. 2025 Aoki T, Nishida N, Kurebayashi Y, Sakai K, Fujiwara N, Tsurusaki M, Hanaoka K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Ueshima K, Minami Y, Takebe A, Murase T, Kamei K, Nakai T, Mastumoto I, Nishio K, **Kudo M\***: Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway. **Clin Mol Hepatol** 31:981-1002, 2025. (IF=16.9)
47. 2025 Kono M, Komeda Y, Kashida H, Hagiwara S, Yoshida A, Omoto S, Takenaka M, Tsuji N, Tribonias G, **Kudo M**: A case of human epidermal growth factor receptor 2-positive colon cancer with invasive micropapillary carcinoma component. **DEN Open** 6:e70184, 2025. (IF=1.5)

2025

英文論文

48. 2025 Chan SL, Sun HC, Xu Y, Zeng H, El-Serag HB, Lee JM, Schwartz ME, Finn RS, Seong J, Wang XW, Paradis V, Abou-Alfa GK, Rimassa L, Kao JH, Zhang BH, Llovet JM, Bruix J, Yip TCF, Sun VW, Wong GLH, Chan LL, Liu MQ, Gao Q, Shen F, Kelley RK, Cheng AL, Kurosaki M, Toyoda H, Chen WX, Murakami T, Liang P, Zucman-Rossi J, Minami Y, Miyayama S, Wang K, Man K, Hasegawa K, Li Q, Tsuchiya K, Xu Li, Chew V, Chow P, Hoshida Y, Lujambio A, Ng IOL, Sakamoto M, Park YN, Yau T, **Kudo M\***, Fan J, Zhou J: The Lancet Commission on addressing the global hepatocellular carcinoma burden: Comprehensive strategies from prevention to treatment. **Lancet** 406:731-778, 2025. (IF=88.5)
49. 2025 Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Ishikawa T, Tajiri K, Ohama H, Toyoda H, Ogawa C, Nishimura T, Hanataka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Kanayama Y, Tada F, Nakamura S, Nouse K, Morishita A, Ito K, Okubo T, Arai T, Tsutsui A, Tanaka H, Noritake H, Kaibori M, Hiasa Y, **Kudo M**, Kumada T: Clinical utility of a prognostic scoring system based on LDH and CRP in HCC patients receiving atezolizumab plus bevacizumab. **Liver Int** 45:e70286, 2025. (IF=5.2)
50. 2025 Vitiello F, Tada T, Suda G, Shimose S, **Kudo M**, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Scartozzi M, Tamburini E, Foschi FG, Persano M, Rossari F, Foti S, Camera S, De Cobelli F, Aldrighetti L, Cascinu S, Casadei-Gardini A, Rimini M: Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population. **Semin Oncol** 52:152348, 2025. (IF=2.5)

## 2025

### 英文論文

51. 2025 Wang K, Feng JK, Yu H, Cheng YQ, Xiang YJ, Liu ZH, Qin YY, Liu EY, Shan Y, Fan C, Zhai J, He DD, Zhou HK, Tang Y, Shi J, Guo W, Yan ML, Yu LW, **Kudo M**, Cheng S: Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: A single-arm, phase 2 trial. **Signal Transduct Target Ther** 10:328, 2025. (IF=52.7)
52. 2025 Kurimoto M, Watanabe T, Otsuka Y, Hara A, Omaru N, Sekai I, Masuta Y, Masaki S, Kamata K, Minaga K, Honjo H, Arai Y, Yamashita K, **Kudo M**: Vitamin A deficiency enhances susceptibility to experimental autoimmune pancreatitis through activation of CD4+ T cells expressing CXCR3 and secreting CCL25. **Clin Exp Immunol** 219:uxaf060, 2025. (IF=3.8)
53. 2025 Kawano K, Takenaka M, Mine K, Kawano R, Kagoshige D, Nishi K, **Kudo M**: The two-layered cross technique for post-over-the-scope clip bleeding. **Endoscopy** 57:E954-E956, 2025. (IF=12.8)
54. 2025 **Kudo M**, Ren Z, Finn RS, Llovet JM; LEAP-012 investigators: Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial - Authors' reply. **Lancet** 406:694, 2025. (IF=88.5)
55. 2025 Takenaka M, **Kudo M**: Contribution of endoscopy in the diagnosis and treatment of patients with primary sclerosing cholangitis. **Digest Endosc** 37:1089-1091, 2025. (IF=4.7)
56. 2025 Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Tamai H, Matsuura T,

2025

英文論文

- Komatsu S, Ueda Y, Nakamura Y, Yoshida O, Nakamura S, Enomoto H, Kaibori M, Fukumoto T, Hiasa Y, **Kudo M**, on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group: Neutrophil–lymphocyte ratio predicts overall survival in patients with HCC Treated with durvalumab plus tremelimumab. **Hepatol Res** 55:1285-1295, 2025. (IF=3.4)
57. 2025 Minaga K, **Kudo M**: Role and challenges of endoscopic ultrasonography-guided tissue acquisition for para-aortic lymph node staging. **Digest Endosc** 37:1096-1098, 2025. (IF=4.7)
58. 2025 Ueshima K, Tsuchiya K, Yamashita T, Shimose S, Numata K, Kodama Y, Itoh S, Tanaka Y, Kuroda H, Ohkawa K, Kuzuya T, Ikeda M, Kooka Y, Aikata H, Hiraoka A, Moriguchi M, Tateishi R, Ogasawara S, Yamamoto K, **Kudo M\***: Atezolizumab plus bevacizumab for TACE-unsuitable Intermediate-Stage HCC beyond up-to-7 criteria: Final analysis of REPLACEMENT. **Liver Int** 45:e70379, 2025. (IF=5.2)
59. 2025 Watanabe T, **Kudo M**: Roles of deubiquitinases OTUD3 and OTUD5 in Inflammatory bowel diseases. **Intern J Mol Sci** 26:9924, 2025. (IF=4.9)
60. 2025 Ogawa R, Kawamura J, Ashworth ET, Park SB, Hall DJ, **Kudo M**, Hoh CK, Vera DR: Multimodal tilmanocept for preoperative imaging and fluorescence-guided surgery of porcine lateral pelvic sentinel lymph nodes. **Sci Rep** 15:37441, 2025. (IF=3.9)
61. 2025 **Kudo M\***: Fluorine-18 fluorodeoxyglucose positron emission tomography: A potential imaging biomarker for predicting response to combination immunotherapy in hepatocellular carcinoma. **Liver Cancer** 14:511-517, 2025. (IF=9.1)
62. 2025 Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K,

2025

英文論文

- Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Ogawa C, Nishimura T, Hanataka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Tada F, Nakamura S, Nakamura Y, Miyake T, Yoshida O, Nouse K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Matsuura T, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Matsui K, Kaibori M, Fukumoto T, Hiasa Y, **Kudo M**, Kumada T: Potential role of geriatric nutritional risk index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma. **J Gastroenterol** 60:1427-1436, 2025. (IF=5.5)
63. 2025 Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Noritake H, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Tamai H, Matsuura T, Komatsu S, Ueda Y, Nakamura Y, Yoshida O, Matsui K, Nakamura S, Enomoto H, Kaibori M, Fukumoto T, Hiasa Y, **Kudo M**; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts From 48 Clinics in Japan (HCC 48) Group: Safety and efficacy of durvalumab plus tremelimumab in older individuals with unresectable hepatocellular carcinoma: A multicenter analysis. **Hepatol Res** 55:1507-1517, 2025. (IF=3.4)
64. 2025 Ohba A, Ozaka M, Mizusawa J, Okusaka T, Kobayashi S, Yamashita T, Ikeda M, Yasuda I, Sugimori K, Sasahira N, Ikezawa K, Miki I, Okano N, Mizuno N, Furukawa M, Shirakawa H, Sano Y, Katayama H, Furuse J, Ueno M, Okamura K, Komatsu Y, Katanuma A, Unno M, Shirakawa H, Yamaguchi H, Shimizu S, Ikeda M, Ishii H, Kato N, Okusaka T, Nagashima F, Itoi T, Kojima Y, Kuramochi H, Sasahira N, Sano K, Takahashi

2025

英文論文

- S, Sunakawa Y, Ueno M, Kumamoto Y, Sugimori K, Shioji K, Yasuda I, Yamashida T, Tsuji K, Yamazaki K, Hara K, Hatano E, Eguchi H, **Kudo M**, Ohkawa K, Gotoh K, Satoi S, Tobimatsu K, Hirono S, Miki I, Kitano M, Nagano H, Asagi A, Okabayashi T, Furukawa M, Fujimori N, Nakao K, Ido A: Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin or S-1, irinotecan, and oxaliplatin versus nab-paclitaxel + gemcitabine in metastatic or recurrent pancreatic cancer (GENERATE, JCOG1611): A randomized, open-label, phase II/III trial. **J Clin Oncol** 43:3345-3354, 2025. (IF=41.9)
65. 2025 Rimassa L, Chan SL, Sangro B, Lau G, **Kudo M**, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler OV, Bouattour M, Van Dao T, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Paskow MJ, Ran D, Xynos I, Kurland JF, Negro A, Abou-Alfa GK: Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. **J Hepatol** 83:899-908, 2025. (IF=33.0)
66. 2025 Lombardi P, Kim JS, Manfredi GF, Celsa C, Fulgenzi CAM, D'Alessio A, Stefanini B, Doshi NC, Warmington E, Marron TU, Pinter M, Scheiner B, Kang B, Lim HY, Hsu WF, Wietharn B, Silletta M, Parisi A, Lin CY, Dalbeni A, Masi G, Schönlein M, von Felden J, Piscaglia F, Galle PR, **Kudo M**, Pressiani T, Rimassa I, Pirisi M, Cabibbo G, Chon HJ, Pinato DJ: Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN Study. **JHEP Reports** 7:101595, 2025. (IF=7.5)
67. 2025 Mesropian A, Gris-Oliver A, Balaseviciute U, Potdar AA, Kimura T, Shen J, Torres-Marcén M, Abril-Fornaguera J, Piqué-Gili M, Camell-Raventos D, Peix J, Fernández-Martínez E, Huguet-Pradell J, Keraite I, Esteban-Fabro R, Bárcena-Varela M, Lindblad KE, Lujambio A, Guccione E, Thung S, Ikeda M, **Kudo M**, Sia D, Pinyo R, Llovet JM: E7386 enhances

2025

英文論文

lenvatinib's antitumor activity in preclinical models and human hepatocellular carcinoma. **Clin Cancer Res** 31:5037-5050, 2025. (IF=10.2)

68. 2025 Celsa C, Cabibbo G, Fulgenzi CAM, Battaglia S, Enea M, Scheiner B, D'Alessio A, Manfredi GF, Stefanini B, Nishida N, Galle PR, Schulze K, Wege H, Ciccia R, Hsu WF, Vivaldi C, Wietharn B, Lin RP, Pirozzi A, Pressiani T, Dalbeni A, Natola LA, Auriemma A, Rigamonti C, Burlone M, Parisi A, Huang YH, Lee PC, Ang C, Marron TU, Pinter M, Cheon J, Phen S, Singal AG, Gampa A, Pillai A, Roehlen N, Thimme R, Vogel A, Soror N, Ulahannan S, Sharma R, Sacerdoti D, Pirisi M, Rimassa L, Lin CY, Saeed A, Masi G, Schönlein M, von Felden J, **Kudo M**, Cortellini A, Chon HJ, Cammà C, Pinato DJ: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment. **Hepatology** 81:837-852, 2025. (IF=15.8)
69. 2025 Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, **Kudo M**, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Mascia L, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Rimini M: Lenvatinib versus sorafenib second-line therapy in patients with hepatocellular carcinoma progressed to atezolizumab plus bevacizumab: A retrospective real-world study. **Oncology** 103:456-468, 2025. (IF=1.8)

2025

英文論文

70. 2025 **Kudo M\***, Yamashita T, Finn RS, Galle PR, Ducreux M, Cheng AL, Tsuchiya K, Sakamoto N, Hige S, Take R, Yamada K, Nakagawa Y, Takahashi H, Ikeda M: Depth and duration of response are associated with survival in patients with unresectable hepatocellular carcinoma: Exploratory analyses of IMbrave150. **Liver Cancer** 14:539-554, 2025. (IF=9.1)
71. 2025 Morita M, Takita M, Nishida N, **Kudo M**: Giant sister Mary Joseph`s nodule in hepatocellular carcinoma. **Am J Gastroenterol** 120:1686, 2025. (IF=7.6)
72. 2025 Matsubara T, Takita M, Sekai I, Omaru N, Okai N, Morita M, Kamata K, Minaga K, Watanabe T, **Kudo M**: Development of diffuse large B cell lymphoma in a patient with systemic lupus erythematosus within two years after the initiation of anifrolumab and mycophenolate mofetil treatment. **Intern Med** 64:3044-3050, 2025. (IF=1.1)
73. 2025 Narikawa T, Kamata K, Komaki T, Takenaka M, **Kudo M**: Difficult case of endoscopic ultrasonography guided-choledochogastrostomy salvaged by using a stiff guidewire. **Int J Gastroint Int** 14:28-31, 2025. (IF=0.2)
74. 2025 **Kudo M\***: Lancet Commission 2025 calls for urgent global action: 60% of liver cancers are preventable. **Liver Cancer** 14:679-686, 2025. (IF=9.1)
75. 2025 Nagai T, Komeda Y, Yoshida S, Handa K, Masaki S, Kono M, Honjo H, Matsui S, Tsuji N, Kashida H, **Kudo M**: Caloric restriction is associated with enhanced clinical outcomes in hospitalized patients with ulcerative colitis. **Gastro Hep Adv** 5:100842, 2025. doi: 10.1016/j.gastha.2025.100842
76. 2025 Kim JS, Wong J, Chen SC, Tai D, Yang H, Kim Y, Kang B, Kim I, Kim H, An C, Jang SJ, **Kudo M**, Lim HY, Kim C, Yau T, Chon

2025

英文論文

- HJ: Outcomes of nivolumab plus ipilimumab after atezolizumab plus bevacizumab in advanced HCC: An International multicentre study. **Liver Int** 46:e70493, 2025. doi: 10.1111/liv.70493. (IF=5.2)
77. 2025 Ueshima K, Nishida N, Hagiwara S, Minami Y, Ida H, Takita M, Chishina H, Morita M, Aoki T, Hamano T, Take R, Watanabe C, Asoh K, Tanaka A, **Kudo M**: No correlation between proteinuria and renal function in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: ARISE study. **Cancers** 17:3826, 2025. doi: 10.3390/cancers17233826. (IF=4.4)
78. 2025 Minaga K, Hara A, **Kudo M**: Reconsidering sedation for endoscopic retrograde cholangiopancreatography: The potential of remimazolam. **Digest Endosc** 38:e70034, 2025. doi: 10.1111/den.70034. (IF=4.7)
79. 2025 Omaru N, Takita M, Sekai I, Minaga K, Hagiwara S, Kojima M, Maenishi O, Ueda Y, Watanabe T, **Kudo M**: Cytomegalovirus-induced intrahepatic cholestasis complicated by hemophagocytic syndrome in an immunocompetent adult. **Clin J Gastroenterol** 19:241-248, 2025. (IF=0.9)
80. 2025 **Kudo M**, Ueshima K, Tsuchiya K, Yamashita T, Shimose S, Numata K, Kodama Y, Itoh S, Tanaka Y, Kuroda H, Aikata H, Hiraoka A, Moriguchi M, Tateishi R, Ogasawara S, Yamamoto K, Ikeda M: Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT Study. **Liver Cancer** 15:104-116, 2025. (IF=9.1)
81. 2025 Asaoka Y, Tateishi R, Yamada Y, Kokudo T, Saito A, Hasegawa K, Iijima H, Kato N, Shimada M, Hatano E, Fukumoto T, Murakami T, Yano H, Yoshimitsu K, Kurosaki M, Sakamoto M,

**2025**

**英文論文**

Matsuyama Y, **Kudo M**, Miyata H, Kokudo N: A newly launched nationwide database revealed real-world evidence on systemic therapy for hepatocellular carcinoma in Japan: Hepatoma Registry of Integrating and Aggregating Eelectric health record (HERITAGE). **Liver Cancer** 15:77-89, 2025. (IF=9.1)